Introduction {#section6-1179544117751434}
============

Psoriasis is a chronic, complex autoimmune disease with characteristic reddish patches covered by silvery-white scales. It is quite common and affects approximately 120 to 180 million people worldwide.^[@bibr1-1179544117751434]^ The prevalence of psoriasis varies significantly depending mainly on race, geographic location, genetics, environmental factors, and ethnicity.^[@bibr2-1179544117751434][@bibr3-1179544117751434][@bibr4-1179544117751434][@bibr5-1179544117751434][@bibr6-1179544117751434]--[@bibr7-1179544117751434]^ In Saudi Arabia, its prevalence is 1% to 5% of all skin disorders.^[@bibr8-1179544117751434]^ Psoriasis occurs in both sexes and most of the patients (75%) develop disease before the age of 40 years. Its cause is multifactorial, involving both genetic and environmental factors. Psoriasis depicts a number of characteristics which are also found in other autoimmune diseases suggesting a common causal pathway or mechanism.^[@bibr9-1179544117751434],[@bibr10-1179544117751434]^

The molecular studies on psoriasis have helped to understand the pathogenesis of psoriasis and comorbidities,^[@bibr11-1179544117751434]^ and a number of gene loci have been associated with susceptibility/severity of psoriasis.^[@bibr2-1179544117751434],[@bibr12-1179544117751434]^ These association studies suggested that the pathogenesis of psoriasis involves skin barrier function, innate and adaptive immunity, gene-gene, and gene-environment interactions. As psoriasis is highly heritable and gene loci identified till date do not fully account for it, many genetic as well as environmental factors and their interaction might be involved in the etiopathogenesis.^[@bibr13-1179544117751434]^

It has been confirmed that psoriasis is at least partially mediated by activated T cells.^[@bibr14-1179544117751434],[@bibr15-1179544117751434]^

Typically, the inflammatory process is followed by hyperproliferation of the epidermis, leading to terminal differentiation of keratinocytes. Protein tyrosine phosphatase nonreceptor 22 (*PTPN22*) gene is located on chromosomes 1p13.3 to p13.1 and encodes a lymphoid-specific phosphatase (Lyp). Lyp is an intracellular protein tyrosine phosphatase and is physically bound through proline-rich motif to the SH3 domain of the C-terminal Src kinase (Csk), which suppresses kinases mediating T-cell activation.^[@bibr16-1179544117751434]^ Although Lyp functions as a negative regulator of T cells,^[@bibr17-1179544117751434]^ however, it also plays a role in B-cell signaling.^[@bibr18-1179544117751434]^ It targets various signaling intermediates involved in T-cell receptor signaling and may work at various levels in signaling cascade.

A single-nucleotide polymorphism (SNP) in exon 14 of the *PTPN22* gene 1858C/T (rs2476601) has been associated with a number of autoimmune diseases and considered as a risk factor due to significant production of autoantibodies.^[@bibr19-1179544117751434][@bibr20-1179544117751434][@bibr21-1179544117751434][@bibr22-1179544117751434][@bibr23-1179544117751434][@bibr24-1179544117751434][@bibr25-1179544117751434][@bibr26-1179544117751434][@bibr27-1179544117751434]--[@bibr28-1179544117751434]^ However, a few inconsistent reports on the association of *PTPN22* gene polymorphism and psoriasis are available, and further testing in different ethnic cohorts is required to make sure whether these findings represent genuine associations. In this study, we investigated the association of variants of PTPN22 (1858C/T) (R620W) with the susceptibility to psoriasis in Saudi patients.

Materials and Methods {#section7-1179544117751434}
=====================

Subjects {#section8-1179544117751434}
--------

Our study subjects (n = 306) comprised 106 patients with psoriasis and 200 matched healthy controls from same ethnic population visiting Dermatology Clinic, Prince Sultan Military Medical City (PSMMC), Riyadh, Saudi Arabia. All cases and controls were biologically unrelated Saudis. They were examined and diagnosed by dermatologists as described elsewhere.^[@bibr2-1179544117751434]^ The demographic and other information were collected using a questionnaire. The diagnosis was based on clinical findings, skin changes, and the location of the condition on the body. The Psoriasis Area and Severity Index (PASI) was determined following the work by Schmitt and Wozel.^[@bibr29-1179544117751434]^ Patients diagnosed with arthritis prior to psoriasis were excluded from the study. All subjects gave written consent to participate in this study. Of 106 confirmed patients with psoriasis, 42 were women and 64 were men with the mean age of 37 ± 15.5 years and duration of disease ranging from 1 to 20 (mean: 9 ± 4.5) years, age of onset of diseases was 15 to 55 years with female to male ratio of 1:1.52. Among the healthy controls, 70 were women and 130 were men with the mean age of 36 ± 10 years. We calculated the power of study online: <http://www.stat.ubc.ca/~rollin/stats/ssize/caco.html>.

Patients or controls with any history of autoimmune disorders were excluded from the study. To minimize genetic heterogeneity, control subjects having first-degree or second-degree relative with psoriasis or any other autoimmune disorders were also excluded.

The ethical committee of PSMMC approved the protocol of the study. Inclusion criterion was that all patients must be diagnosed with plaque psoriasis for at least 1 year. Exclusion criteria for both cases and controls were coexisting inflammatory skin disease, autoimmune diseases renal/liver failure, hypothyroidism, and systemic therapy and smoking.

Peripheral blood samples collected from the patients with psoriasis and controls were brought to the laboratory in vacuum flask with ice. Genomic DNA was extracted from the blood using QIAamp DNA Mini Kit (Qiagen, Valencia, CA, USA). Genomic DNA was amplified using tetra-primer amplification refractory mutation system-polymerase chain reaction (PCR) method for detection of PTPN22 (R620W) (rs2476601) polymorphism.^[@bibr30-1179544117751434]^ Two external primers (forward outer primer: 5′-CTCACACATCAG CTTCCCAAAGTG-3′ and reverse outer primer: 5′-CAACTTTACTGATAATGTTGCTTCA ACGGA-3′) and 2 internal primers (forward inner primer: 5′-CAACCACAATAAATG ATTCAGGTGTACG-3′, reverse inner primer: 5′-ATCCCCCCTCCACTTCCTGGAT-3′) were used. Product sizes were 213 and 151 bp (base pairs) for the C and T alleles, respectively, whereas the product size of the internal control was 314 bp. The PCR was performed using 5× FIREPol Master Mix (Solis BioDyne, Tartu, Estonia) following manufacturer's protocol. The PCR cycling conditions were as follows: 5 minutes at 95°C followed by 30 cycles of 30 seconds at 95°C, 30 seconds at 64°C, and 30 seconds at 72°C and 10 minutes at 72°C. The PCR products were electrophoresed on 2% agarose gels and photographed. We regenotyped 25% of the samples (randomly selected) to verify the initial results and ensure genotyping quality.

Statistical analysis {#section9-1179544117751434}
--------------------

The genotype and allele frequencies were analyzed with the Fisher exact test using CalcFisher software. Errors due to multiple comparison tests were minimized by Bonferroni correction. Both *P* values are summarized in [Table 1](#table1-1179544117751434){ref-type="table"}. Odds ratio interpreted as relative risk (RR), etiologic fraction (EF), and preventive fraction (PF) was calculated as described elsewhere.^[@bibr31-1179544117751434],[@bibr32-1179544117751434]^

###### 

Genotype and allele frequencies of *PTPN22* variants in patients with psoriasis and matched healthy controls.

![](10.1177_1179544117751434-table1)

  Genotype/allele   Psoriasis (n = 106)   Control (n = 200)   *P* value                                                                                                              RR      EF^[a](#table-fn3-1179544117751434){ref-type="table-fn"}^/PF
  ----------------- --------------------- ------------------- ---------------------------------------------------------------------------------------------------------------------- ------- --------------------------------------------------------------
  CC                67 (63.21)            185 (92.50)         \<.001^[b](#table-fn4-1179544117751434){ref-type="table-fn"}^,[\*](#table-fn5-1179544117751434){ref-type="table-fn"}   0.139   0.622
  CT                39 (36.79)            15 (7.50)           \<.001^[b](#table-fn4-1179544117751434){ref-type="table-fn"}^,[\*](#table-fn5-1179544117751434){ref-type="table-fn"}   7.151   0.621^[a](#table-fn3-1179544117751434){ref-type="table-fn"}^
  TT                0 (0)                 0 (0)               ---                                                                                                                    ---     ---
  C allele          173 (81.60)           385 (96.25)         \<.001^[b](#table-fn4-1179544117751434){ref-type="table-fn"}^,[\*](#table-fn5-1179544117751434){ref-type="table-fn"}   0.173   0.597
  T allele          39 (18.40)            15 (3.75)           \<.001^[b](#table-fn4-1179544117751434){ref-type="table-fn"}^,[\*](#table-fn5-1179544117751434){ref-type="table-fn"}   5.764   0.596^[a](#table-fn3-1179544117751434){ref-type="table-fn"}^

Abbreviations: EF, etiologic fraction; PF, preventive fraction; RR, relative risk.

Number of allele/genotype is represented as No. (%).

Data for EF.

Statistically significant using Fisher exact test.

*P *\< .004---Bonferroni corrected.

Results {#section10-1179544117751434}
=======

In this case-control study, the allele and genotype frequencies of PTPN22 (1858C/T) polymorphism in cases with psoriasis and unrelated matched controls were determined. The control/case ratio of 1.88:1 yielded a power of 90% with sample size of 106 patients with psoriasis and 200 controls assuming a prevalence of 3.2% of all dermatologic diseases. Among patients with psoriasis, the female to male ratio was 1:1.52.

The distributions of genotypes and alleles of PTPN22 (1858C/T) polymorphism in psoriasis and control groups are shown in [Tables 1](#table1-1179544117751434){ref-type="table"} and [2](#table2-1179544117751434){ref-type="table"}. The amplification of different genotypes is shown in [Figure 1](#fig1-1179544117751434){ref-type="fig"}. In patients and controls, the genotype and allele frequency distributions of the PTPN22 (1858C/T) were in the Hardy-Weinberg equilibrium. The frequencies of alleles and genotypes of PTPN22 (1858C/T) polymorphism were significantly different in patients and control ([Table 1](#table1-1179544117751434){ref-type="table"}).

###### 

Genotype and allele frequencies of *PTPN22* variants in male and female patients with psoriasis.

![](10.1177_1179544117751434-table2)

  Genotype/allele   Male (n = 64)   Female (n = 42)   *P* value   RR      EF^[a](#table-fn8-1179544117751434){ref-type="table-fn"}^/PF
  ----------------- --------------- ----------------- ----------- ------- --------------------------------------------------------------
  CC                42 (65.62)      25 (59.52)        .543        1.298   0.055^[a](#table-fn8-1179544117751434){ref-type="table-fn"}^
  CT                22 (34.38)      17 (40.48)        .543        0.770   0.069
  TT                0 (0)           0 (0)             ---         ---     ---
  C allele          106 (82.81)     67 (79.76)        .591        1.223   0.012^[a](#table-fn8-1179544117751434){ref-type="table-fn"}^
  T allele          22 (17.19)      17 (20.24)        .591        0.818   0.016

Abbreviations: EF, etiologic fraction; PF, preventive fraction; RR, relative risk.

Number of allele/genotype is represented as No. (%).

Data for EF.

![Amplification of *PTPN22* (C1858T) polymorphism.\
Lane M: 100-bp DNA marker; lanes 1, 2, and 4: amplification of genotype CC; lane 3: amplification of genotype CT, 213-bp band for allele C, 151-bp band for allele T, and 314-bp band for internal control.](10.1177_1179544117751434-fig1){#fig1-1179544117751434}

The frequency of polymorphic allele T encoding tryptophan (W) was significantly increased, whereas that of allele C encoding arginine (R) decreased in patients as compared with controls (*P *\< .001, *P *\< .004---Bonferroni corrected). The frequency of heterozygous genotype (CT) was detected only in 7.5% (15/200) of healthy controls corresponding to a minor allele frequency of 0.037, whereas it was higher in patients as compared with controls (*P *\< .001, *P *\< .004---Bonferroni corrected). The frequency of CC genotype of PTPN22 (1858C/T) polymorphism was significantly lower (*P *\< .001, *P *\< .004---Bonferroni corrected) in patient group. The homozygous genotype TT was absent in both cases and controls.

Sex-wise stratification of genotyping results showed that frequencies of allele T and CT genotype were more prevalent in the female patients than the male patients without reaching statistical significance ([Table 2](#table2-1179544117751434){ref-type="table"}). This statistically insignificant difference in the frequencies of alleles and genotypes of PTPN22 (1858C/T) polymorphism in male and female patients indicated that there was no effect of sex on prevalence of PTPN22 (1858C/T) polymorphism.

Discussion {#section11-1179544117751434}
==========

The increased frequencies of allele T and genotype CT in our cases as compared with controls showed that the allele T and genotype CT may increase psoriasis susceptibility (RR = 7.151, EF = 0.621 and RR = 5.764, EF = 596, respectively). However, the lower frequencies of allele C and genotype CC in patients than controls showed that allele C and genotype CC are less susceptible to psoriasis (RR = 0.139, PF = 0.622 and RR = 0.173 PF = 597, respectively). These results suggested that PTPN22 (1858C/T) polymorphism may be associated with psoriasis susceptibility thus highlighting the role of the immune system in the pathogenesis of psoriasis in our population.

The results of this study on patients with chronic plaque psoriasis clearly indicated an association of +1858T allele of the PTPN22 gene with susceptibility to psoriasis in Saudi population similar to several other autoimmune diseases known to be associated with allele T of PTPN22 polymorphism. However, earlier studies from different geographical regions/ethnic populations on PTPN22 (+1858C/T) polymorphism and psoriasis have reported inconsistent results.^[@bibr33-1179544117751434][@bibr34-1179544117751434][@bibr35-1179544117751434][@bibr36-1179544117751434]--[@bibr37-1179544117751434]^

A meta-analysis suggested that PTPN22 may be among the true psoriasis susceptibility-risk genes.^[@bibr34-1179544117751434]^ Li et al^[@bibr35-1179544117751434]^ analyzed 15 SNPs from 7 putative psoriasis-risk genes in 1448 patients with psoriasis and 1385 control subjects and suggested that PTPN22 is one of the significant risk genes for psoriasis. Although there was no significant association of PTPN22 (+1858C/T) polymorphism with psoriasis in their analysis, however, another polymorphism in PTPN22 gene (rs3789604) was found to be significantly associated with susceptibility of psoriasis. Recently, Chen and Chang^[@bibr33-1179544117751434]^ could not find any significant association of the PTPN22 (+1858T) allele with psoriasis but they reported a strong association of PTPN22 (+1858T) allele with psoriatic arthritis (PsA) and suggested that future studies should be based on gene-environment interaction and attention should be focused on the clinical heterogeneity of the disease together with population stratification.

Earlier, Hüffmeier et al^[@bibr38-1179544117751434]^ also found an association of PTPN22 (+1858T allele) with psoriasis and reported sex variations in susceptibility. Excluding direct link of T allele in psoriasis susceptibility in German patients, they suggested that other susceptibility determinant(s) within noncoding regions of *PTPN22* or its proximity might exist and act independently as a risk factor. The +1858T allele of the PTPN22 gene has also been strongly associated with PsA, a related autoimmune disease.^[@bibr23-1179544117751434],[@bibr39-1179544117751434]^ Recently, a study by Budu-Aggrey et al^[@bibr40-1179544117751434]^ has suggested that several non--HLA risk loci including PTPN22 affect PsA susceptibility. They added that there is a complete genetic overlap between psoriasis and PsA susceptibility loci and about a third of people who have psoriasis will get PsA. People with severe psoriasis could have a greater chance of getting PsA. About 40% of people who get PsA have relatives with it or with psoriasis.

The *PTPN22* (1858C/T) variants are considered important non-HLA common susceptibility determinants for T-cell--mediated autoimmune diseases.^[@bibr41-1179544117751434],[@bibr42-1179544117751434]^ The PTPN22 (1858C/T) polymorphism results into a change of arginine (R) to a tryptophan (W) at position 620 and interrupts the interaction of Csk with Lyp and stops the formation of complex ultimately suppressing the activation of T cell. It has been shown by in vitro experiments that C allele of *PTPN22* binds more efficiently to Csk than T allele suggesting thereby that T cells expressing the T allele may be hyperresponsive and T-allele carriers may be prone to autoimmune disorders.^[@bibr20-1179544117751434],[@bibr22-1179544117751434]^ Moreover, the decreased thresholds for T-cell receptor signaling in animal knockout for murine homologue of *PTPN22* confirm a specific role of *PTPN22* in T-cell regulation.^[@bibr43-1179544117751434]^

In contrast, other studies reported no association of this PTPN22 (1858C/T) polymorphism with psoriasis.^[@bibr36-1179544117751434],[@bibr37-1179544117751434],[@bibr44-1179544117751434][@bibr45-1179544117751434]--[@bibr46-1179544117751434]^ Although Smith et al^[@bibr36-1179544117751434]^ found no evidence of association of PTPN22 (R620W) with psoriasis susceptibility, however, they reported an association of other 2 SNPs, namely, rs1217414 and rs3789604, in the *PTPN22* gene with psoriasis. It has been suggested that genetics of psoriasis is complex and there are several susceptibility genes implicated which vary among different ethnic groups.^[@bibr13-1179544117751434],[@bibr47-1179544117751434],[@bibr48-1179544117751434]^ In addition, the gene-environment interaction may play important role in the etiopathogenesis of the disease. Saudi being a close society with high degree of consanguinity and unique environmental conditions together with high-protein diet might have resulted into these variations in association results. Moreover, in genetic association studies where a particular factor or variant has a small effect on the risk, the sample size is instrumental. It is possible that studies reporting no association of PTPN22 (1858T) allele with some autoimmune diseases could be due to lack of power to detect a true association in these studies. Moreover, most of these studies have been performed on the white subjects, and to the best of our knowledge, no work has been done on Middle Eastern populations. This is the first report showing an association of PTPN22 (1858C/T) polymorphism with psoriasis susceptibility in Saudi patients.

In addition, these differences in the results of PTPN22 (1858C/T) polymorphism in psoriasis indicate that the causes of psoriasis may involve different pathogenic mechanisms possibly due to ethnic variations. Ethnic variations in prevalence of PTPN22 (1858C/T) polymorphism have been reported in healthy populations also. It is quite low in Asian and African populations and is virtually absent in Han Chinese.^[@bibr49-1179544117751434][@bibr50-1179544117751434][@bibr51-1179544117751434]--[@bibr52-1179544117751434]^ In Europe, a North-South gradient ranging between 15.5% and 2.1% has been reported in the polymorphic allele frequencies of PTPN22 (1858C/T) polymorphism.^[@bibr19-1179544117751434],[@bibr51-1179544117751434]^

In populations where PTPN22 (1858C/T) (rs2476601) is not associated with autoimmune diseases, other functional variants of *PTPN22* gene and/or SNPs that are in linkage disequilibrium with PTPN22 (1858C/T) might be involved.^[@bibr53-1179544117751434],[@bibr54-1179544117751434]^ The polymorphisms rs2488457, rs3789604, and rs1310182 in *PTPN22* gene have also been associated with several autoimmune diseases in Asian populations.^[@bibr12-1179544117751434]^

The other possible pathway of the cause of psoriasis has been explained on the basis of the fact that there is no citrullinated keratin K1 found in skin samples from patients with psoriasis.^[@bibr55-1179544117751434][@bibr56-1179544117751434][@bibr57-1179544117751434]--[@bibr58-1179544117751434]^ The lack of citrullinated proteins causes excessive cornification and an inflammatory response. Psoriasis is the only disease linked to peptidylarginine deiminase (PAD) dysregulation.^[@bibr56-1179544117751434][@bibr57-1179544117751434][@bibr58-1179544117751434]--[@bibr59-1179544117751434]^ The PTPN22 can prevent protein citrullination by blocking PAD type 4 (PAD-4) enzymes. A molecular link between PTPN22 and PAD-4 has been reported recently.^[@bibr60-1179544117751434]^ PTPN22 (1858C/T) polymorphism which converts R to W promotes the activation signals in lymphocytes and increases autoreactive B cells, decreases production of type I interferon by myeloid cells, and ultimately increases the risk of autoimmune diseases including psoriasis.^[@bibr60-1179544117751434]^

Our results identify PTPN22 (1858C/T) R620W polymorphism as a susceptibility marker for psoriasis in Saudi population and suggest that polymorphism in *PTPN22* may contribute to psoriasis and that can be developed as a biomarker for evaluating psoriasis risk. However, further studies on PTPN22 polymorphisms in larger samples from different geographic locations and ethnicity are warranted.
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